Previous 10 | Next 10 |
Atai Life Sciences (NASDAQ:ATAI) stock gained 4.9% Wednesday days after the firm disclosed insider buying of shares worth ~$540K. 10% owner Apeiron Investment bought 111.6K shares at $4.70-4.90. Apeiron now holds ~1.3M shares in ATAI. ATAI's ownership structure: ATAI stock has declined 3...
NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: PolarityTE, Inc. (NASDAQ: PTE), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), atai Life Sciences N....
Most people in the psychedelics industry believe that the growing superstar of psychedelic medicines is psilocybin—the “psychedelic du jour” as one scientist put it to Psychedelia . But ketamine is quickly changing that perception. Ke...
atai Life Sciences N.V. (ATAI) Q4 2021 Results Earnings Conference Call March 30, 2022, 08:30 AM ET Company Participants Colin Keeler - Manager, Corporate Finance Christian Angermayer - Founder and Chairman Florian Brand - Co-Founder, Chief Executive Officer and Managing Director Srinivas Rao...
ATAI Life Sciences press release (NASDAQ:ATAI): FY GAAP EPS of -$1.21 misses by $0.44. Revenue of $20.37M beats by $3.13M. For further details see: ATAI Life Sciences GAAP EPS of -$1.21 misses by $0.44, revenue of $20.37M beats by $3.13M
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initia...
AER, ATAI, BNTX, CAAS, CWCO, OTCPK:DLMAF, OTCQX:KNTNF, LGMK, MSM, ORTX, PAYX, PTE, OTCQX:TCNNF, TCRT, UPH For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Wednesday's open
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily, psychedelics like DMT, psilocybin, MDMA, and LSD are bein...
Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to co-CEO of the ATMA Journey Centers, David Harder, a quoted in a company press release, “The surge in demand for alternative options to traditional mental health support have fueled...
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...